A Phase 1/2 interventional study of IPG11406 in Lupus Nephritis, sponsored by Nanjing Immunophage Biotech Co., Ltd. Completed at 17 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Nanjing Immunophage Biotech Co., Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.
Among the 96 studies in Lupus Nephritis with a site in China, this one is the 59th largest by enrollment of the 88 interventional ones that give a count, is one of 19 that started in 2025, is one of 10 in phase 1/2, and was the 69th registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 6–18
Beijing GoBroad Hospital · Sites in China
Ages 6–65
Beijing Biotech · Sites in China
Ages 18–70
Nanjing University School of Medicine · Sites in China
Ages 14–65
China Immunotech (Beijing) Biotechnology Co., Ltd. · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 31 · Phase 3 22 · Phase 4 7
First in 1996; this study’s year is marked. 19 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 51 across the 88 interventional studies, 400 across the 7 observational. Of the 34 that completed or were terminated, 11 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 96 have an industry lead sponsor. The 10 most frequent:
Nanjing Immunophage Biotech Co., Ltd is the lead sponsor of 11 studies on the registry; 6 are open to participants now.
Nanjing Immunophage Biotech Co., Ltd has 2 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
17 of the studies in Lupus Nephritis with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT06406205Phase 3Qilu Pharmaceutical Co., Ltd.A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis | 2027-06 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT07236762China Immunotech (Beijing) Biotechnology Co., Ltd.An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases | 2026-11-24 |
| NCT07706998Nanjing UniversityApplication of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 96 studies in Lupus Nephritis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis
This is a multi-center, multi-dose phase Ib/IIa study to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis.
This study has two parts.In Part A1, there will be 3 dose groups, 20 mg bid (Cohort 1), 40 mg bid (Cohort 2), 80 mg bid (Cohort 3).In Cohorts 1 to 3, there will be 3-6 participants in each cohort.In Part A2, dose expansion will be conducted at the proposed recommended Phase 2 dose (RP2D). All subjects will be screened within 28 days before administration, and eligible subjects will be administered and observed for 28 days after screening. In this part, it is planned to recruit about 36 patients with nephritis.
After each cohort has completed the 28-day dosing and evaluation, the safety monitoring committee (SMC) will evaluate the safety and tolerability of IPG11406 based on all accumulated safety data (including follow-up data) and available PK data. Based on the evaluation results of safety and tolerability, the SMC will decide whether to administer the next dose group.Part A1 will determine the recommended Phase 2 dose (RP2D) and maximum tolerated dose (MTD) of IPG11406.
The design of Part B will be finalized based on the results of Part A.
Criteria for Inclusion and Exclusion \<Inclusion Criteria>
(2) Subjects are allowed to be receiving any of the following standard treatment regimens at the time of enrollment: 1) Oral prednisone (or equivalent) monotherapy: a. Treatment duration: ≥ 2 weeks prior to screening and have a stable dose for ≥ 2 weeks prior to enrollment; b. Dose requirements: maximum daily dose: 1 mg/kg/day; 2) Immunosuppressants: a. Permitted medications include: antimalarials, azathioprine, cyclophosphamide, mycophenolate mofetil/mycophenolic acid, methotrexate, cyclosporine A, and tacrolimus; b. Treatment duration: ≥ 12 weeks prior to screening and have a stable dose for ≥ 8 weeks prior to enrollment; c. Dose requirements: hydroxychloroquine ≤ 400 mg/day, azathioprine ≤ 100 mg/day, cyclophosphamide ≤ 800 mg/4 weeks, mycophenolate mofetil/mycophenolic acid ≤ 2 g/day, oral, subcutaneous (SC), or intramuscular methotrexate ≤ 15 mg/week, cyclosporine A ≤ 3 mg/kg/day, tacrolimus ≤ 3 mg/day; 3) Oral prednisone (or equivalent) monotherapy ± hydroxychloroquine sulfate ± ≥ one immunosuppressant a. The above requirements for treatment duration and dose stability of oral (OCS) and immunosuppressants should be met; b. The maximum daily/weekly dose of each drug in 1) and 2) should not be exceeded.
8.Female subjects are required to be non-pregnant and non-lactating during the trial.
9.Subjects who do not have a pregnancy plan, voluntarily take effective measures (see the Appendix for details), and have no sperm or egg donation plan from screening to 6 months after the end of the study.
The subject voluntarily participates in the study, is able to sign the form, and complies with the requirements on the informed consent form.
\<Exclusion Criteria>
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3\~6 subjects will be orally administered with IPD11406 20 mg twice a day. All subjects will undergo screening for 28 days before administration, and those who pass the screening will undergo 28 days of drug administration and observation.
Drug: IPG11406
After cohort 1 complete 28 days of dosing and evaluation, the Safety Monitoring Committee (SMC) will assess the safety and tolerability of IPG11406 based on all accumulated safety data (including follow-up data) and available pharmacokinetic (PK) data. Based on SMC approval, 3\~6 subjects will be orally administered 40 mg with IPD11406 twice a day. All subjects will undergo screening for 28 days before administration, and those who pass the screening will undergo 28 days of drug administration and observation.
Drug: IPG11406
After cohort 2 complete 28 days of dosing and evaluation, the Safety Monitoring Committee (SMC) will assess the safety and tolerability of IPG11406 based on all accumulated safety data (including follow-up data) and available pharmacokinetic (PK) data. Based on SMC approval, 3\~6 subjects will be orally administered 80 mg with IPD11406 twice a day. All subjects will undergo screening for 28 days before administration, and those who pass the screening will undergo 28 days of drug administration and observation.
Drug: IPG11406
Investigational Medical Products: IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage:15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed.
Evaluate the safety and tolerability via assessment of Adverse events
Grades of AE will be assessed according to CTCAE 5.0
Time frame: Up to 58 days
Evaluate the safety and tolerability via Respiration rate of Vital Signs
Changes from baseline, Respiration rate in times per minute
Time frame: Up to 58 days
Evaluate the safety and tolerability via Heart rate of Vital Signs
Changes from baseline, Heart rate in beats per minute
Time frame: Up to 58 days
Evaluate the safety and tolerability via Blood pressure of Vital Signs
Changes from baseline,Blood pressure in mmHg
Time frame: Up to 58 days
Evaluate the safety and tolerability via Body temperature of Vital Signs
Changes from baseline,Body temperature in Celsius degree
Time frame: Up to 58 days
Evaluating the safety and tolerability from Red blood cell count of Laboratory Examination
Changes from baseline of Red blood cell count in whole blood is reported in the form of number.
Time frame: Up to 58 days
Evaluating the safety and tolerability from White blood cell of Laboratory Examination
Changes from baseline of White blood cell count in whole blood is reported in the form of number.
Time frame: Up to 58 days
Evaluating the safety and tolerability from lymphocyte count of Laboratory Examination
Changes from baseline , Lymphocyte count in whole blood is reported in the form of number.
Time frame: Up to 58 days
Evaluating the safety and tolerability from hemoglobin of Laboratory Examination
Changes from baseline , Changes of hemoglobin concentration(g/dL)in whole blood will be recorded.
Time frame: Up to 58 days
Evaluating the safety and tolerability from Laboratory Examination
Changes from baseline of Laboratory Examination (hematology, clinical chemistry, coagulation, urinalysis)
Time frame: Up to 58 days
Evaluating the safety and tolerability from Prothrombin time of Laboratory Examination
Changes from baseline, Prothrombin time (PT) is a screening test for exogenous coagulation factors.
Time frame: Up to 58 days
Evaluating the safety and tolerability from Activated partial thromboplastin time of Laboratory Examination
Changes from baseline, Activated partial thromboplastin time (APTT) is a screening test for endogenous coagulation factors.
Time frame: Up to 58 days
Evaluating the safety and tolerability from total bilirubin concentration of Laboratory Examination
Changes from baseline, Changes of total bilirubin concentration (μmol/L) in serum will be recorded.
Time frame: Up to 58 days
Evaluating the safety and tolerability from direct bilirubin concentratio of Laboratory Examination
Changes from baseline, Changes of direct bilirubin concentration (μmol/L) in serum will be recorded.
Time frame: Up to 58 days
Evaluating the safety and tolerability from ALT of Laboratory Examination
Changes from baseline, Changes of ALT concentration (U/L) in serum will be recorded.
Time frame: Up to 58 days
Evaluating the safety and tolerability from AST of Laboratory Examination
Changes from baseline, Changes of AST concentration (U/L) in serum will be recorded.
Time frame: Up to 58 days
Evaluating the safety and tolerability from creatinine concentration of Laboratory Examination
Changes from baseline, Changes of creatinine concentration (μmol/L) in serum will be recorded.
Time frame: Up to 58 days
Evaluating the safety and tolerability from triglyceridesconcentration of Laboratory Examination
Changes from baseline, Changes of triglycerides (TG) concentration (mmol/L) in serum will be recorded.
Time frame: Up to 58 days
Evaluating the safety and tolerability from urine protein of Laboratory Examination
Changes from baseline, Changes of urine protein will be examined by qualitative test
Time frame: Up to 58 days
Evaluating the safety and tolerability from urine pH value of Laboratory Examination
Changes from baseline, Changes of urine pH value will be recorded.
Time frame: Up to 58 days
Evaluating the safety and tolerability from ventricular rate of Electrocardiogram
Changes from Clinical Significant Changes in 12-Lead Electrocardiogram (ECG) findings for ventricular rate (beats/min)
Time frame: Up to 58 days
Evaluating the safety and tolerability from PR interval of Electrocardiogram
Changes from Clinical Significant Changes in 12-Lead Electrocardiogram (ECG) findings for PR interval (ms)
Time frame: Up to 58 days
Evaluating the safety and tolerability from QRS (ms) of Electrocardiogram
Changes from Clinical Significant Changes in 12-Lead Electrocardiogram (ECG) findings for QRS (ms)
Time frame: Up to 58 days
Evaluating the safety and tolerability from QTc of Electrocardiogram
Changes from Clinical Significant Changes in 12-Lead Electrocardiogram (ECG) findings for QTc (ms),
Time frame: Up to 58 days
Evaluate the impact of oral IPG11406 on biomarkers in patients with Lupus Nephritis
Changes in biomarkers before and after medication administration in patients
Time frame: Up to 58 days
Evaluate the impact of oral administration of IPG11406 on 24-hour urine protein quantitation of proteinuria and renal function in patients with Lupus Nephritis
Measure the changes in 24-hour urine protein quantitation before and after medication administration
Time frame: Up to 58 days
Evaluate the impact of oral administration of IPG11406 on estimated glomerular filtration rate of proteinuria and renal function in patients with Lupus Nephritis
Measure the changes in estimated glomerular filtration rate (eGFR) calculated using the MDRD formula before and after medication administration
Time frame: Up to 58 days
Evaluate the impact of oral administration of IPG11406 on ratio of 24-hour urine protein to urine creatinine of proteinuria and renal function in patients with Lupus Nephritis
Measure the changes in ratio of 24-hour urine protein to urine creatinine before and after medication administration
Time frame: Up to 58 days
Evaluate the impact of oral administration of IPG11406 on proteinuria and renal function in patients with Lupus Nephritis
Measure the changes in 24-hour urine protein quantitation, estimated glomerular filtration rate (eGFR) calculated using the MDRD formula, and the ratio of 24-hour urine protein to urine creatinine before and after medication administration
Time frame: Up to 58 days
Evaluate the pharmacokinetics (PK) characteristics of oral IPG11406 in Maximum Plasma Concentration
PK parameters:Maximum Plasma Concentration \[Cmax\]
Time frame: Up to 28 days
Evaluate the pharmacokinetics (PK) characteristics of oral IPG11406 in Area under the curve
PK parameters (under food effect): Area Under The Curve (AUC)
Time frame: Up to 28 days
Evaluate the pharmacokinetics (PK) characteristics of oral IPG11406 from clearance at steady state
PK parameters (under food effect): clearance at steady state (CLss/F)
Time frame: Up to 28 days
Evaluate the pharmacokinetics (PK) characteristics of oral IPG11406 from T1/2
Elimination half-life (T1/2) after dose
Time frame: Up to 28 days
Evaluate the pharmacokinetics (PK) characteristics of oral IPG11406 in CL by plasma concentration of whole blood sample
Clearance (CL) after dose
Time frame: Up to 28 days
Evaluate the preliminary efficacy of oral IPG11406 from peripheral blood T lymphocyte counts and proportion
Changes in peripheral blood T lymphocyte counts and proportions before and after medication administration
Time frame: Up to 58 days
Evaluate the preliminary efficacy of oral IPG11406 from Autoantibodies
Changes in autoantibodies before and after medication administration
Time frame: Up to 58 days
Evaluate the preliminary efficacy of oral IPG11406 from Relative count of lymphocyte subsets
Changes in Relative count of lymphocyte subsets before and after medication administration
Time frame: Up to 58 days
Evaluate the preliminary efficacy of oral IPG11406 from cytokines
Changes in cytokines before and after medication administration
Time frame: Up to 58 days
Evaluate the preliminary efficacy of oral IPG11406 from Th1/Th2 detection
Changes in Th1/Th2 before and after medication administration
Time frame: Up to 58 days
Evaluate the preliminary efficacy of oral IPG11406 from Routine immunological tests
Changes in Routine immunological tests before and after medication administration
Time frame: Up to 58 days
Evaluate the preliminary efficacy of oral IPG11406 in patients with Lupus Nephritis
Changes in peripheral blood B lymphocyte and T lymphocyte counts and proportions, serum albumin, blood creatinine, blood uric acid, blood urea nitrogen (BUN), white blood cells, blood neutrophils, C-reactive protein, complement C3, complement C4, immunoglobulins (IgG, IgA, IgM, IgE), anti-ds-DNA antibody, anti-nuclear antibody, anti-cardiolipin antibody (A/G/M, IgG, IgM), anti-histone antibody, anti-nucleosome antibody, anti-ribosomal P protein antibody, anti-sm antibody, anti-SSA antibody, IL-6, IL-17, IL-2, IL-1β, IL-10, IFN-α, TNF-α, ferritin, and SLEDAI-2K score before and after medication administration
Time frame: Up to 58 days
Evaluate the preliminary efficacy of oral IPG11406 from 24-hour urine protein test
Changes in 24-hour urine protein test before and after medication administration
Time frame: Up to 58 days
Evaluate the preliminary efficacy of oral IPG11406 from Serum ferritin
Changes in Serum ferritin before and after medication administration
Time frame: Up to 58 days
Evaluate the preliminary efficacy of oral IPG11406 from Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI-2K) score
Changes in SLEDAI-2K score before and after medication administration。 Minimum and Maximum Values: The SLEDAI-2K score ranges from 0 (indicating no disease activity) to a maximum possible score that depends on the specific items being scored. However, in practical clinical use, the maximum score is typically much lower than the theoretical maximum, as not all items will be positive in any given patient. The exact maximum score can vary slightly depending on the specific version of the SLEDAI-2K being used, but it is generally well below 100. In the SLEDAI-2K, higher scores indicate a worse outcome. This is because the scale assigns points based on the presence and severity of various lupus manifestations, such as arthritis, rash, fever, and organ involvement. Therefore, as the score increases, it reflects greater disease activity and potentially more severe disease manifestations.
Time frame: Up to 58 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in Jun 2026, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IPG11406
Nanjing Immunophage Biotech Co., Ltd